Evidence map›Paper›PMID 37198208›Full record

ArticleScientific reports2023

A novel insight on SARS-CoV-2 S-derived fragments in the control of the host immunity.

Thais Sibioni Berti Bastos, André Guilherme Portela de Paula, Rebeca Bosso Dos Santos Luz, Anali M B Garnique, Marco A A Belo, Silas Fernandes Eto, Dayanne Carla Fernandes, Fausto Klabund Ferraris, Leticia Gomes de Pontes, Tábata Takahashi França and 23 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Thais Sibioni Berti BastosDepartment of Pathology, Federal University of Parana, Curitiba, Brazil.
André Guilherme Portela de PaulaDepartment of Pathology, Federal University of Parana, Curitiba, Brazil.
Rebeca Bosso Dos Santos LuzDepartment of Pathology, Federal University of Parana, Curitiba, Brazil.
Anali M B GarniqueDepartment of Cell Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Marco A A BeloBrasil University, Descalvado, São Paulo, Brazil.
Silas Fernandes EtoCenter of Excellence in New Target Discovery (CENTD) Special Laboratory, Butantan Institute, São Paulo, Brazil.
Dayanne Carla FernandesVeterinarian, São Paulo, Brazil.
Fausto Klabund FerrarisDepartment of Pharmacology and Toxicology, Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil.
Leticia Gomes de PontesLaboratory of Human Immunology, Department Immunology, Institute Biomedical Sciences, University São Paulo, São Paulo, Brazil.
Tábata Takahashi FrançaLaboratory of Human Immunology, Department Immunology, Institute Biomedical Sciences, University São Paulo, São Paulo, Brazil.
Leonardo José Gil BarcellosLaboratory of Fish Physiology, Graduate Program of Bioexperimentation, University of Passo Fundo, Santa Maria, Brazil.
Flavio P VerasCenter of Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, São Paulo, Brazil.
Pamela BermejoLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Giovanna GuidelliLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Carla ManeiraLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Fellipe da Silveira Bezerra de MelloLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Gleidson TeixeiraLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Gonçalo Amarante Guimarães PereiraLaboratório de Genômica e bioEnergia (LGE), Institute of Biology - Unicamp, Campinas, Brazil.
Bianca H Ventura FernandesLaboratório de Controle Genético e Sanitário, Diretoria Técnica de Apoio ao Ensino e Pesquisa, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Paulo R S SanchesInstituto de Química, Universidade Estadual Paulista, Araraquara, SP, Brazil.
Helyson Lucas Bezerra BrazDepartment of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.
Roberta Jeane Bezerra JorgeDepartment of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.
Guilherme MalafaiaBiological Research Laboratory, Goiano Federal Institute, Urutai Campus, Urutaí, GO, Brazil.
Eduardo M CilliInstituto de Química, Universidade Estadual Paulista, Araraquara, SP, Brazil.
Danilo da Silva OlivierIntegrated Sciences Center, Federal University of Tocantins, Araguaína, TO, Brazil.
Marcos Serrou do AmaralInstitute of Physics, Federal University of Mato Grosso do Sul, Campo Grande, MS, 79070-900, Brazil.
Renata J MedeirosLaboratory of Physiology, INCQS/Fiocruz Zebrafish Facility, Department of Pharmacology and Toxicology, National Institute for Quality Control in Health, Rio de Janeiro, Brazil.
Antonio Condino-NetoLaboratory of Human Immunology, Department Immunology, Institute Biomedical Sciences, University São Paulo, São Paulo, Brazil.
Luciani R CarvalhoLaboratório de Controle Genético e Sanitário, Diretoria Técnica de Apoio ao Ensino e Pesquisa, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Glaucia M Machado-SantelliLaboratory of Cellular and Molecular Biology, Department of Cell and Developmental Biology, Institute of Biomedical Science, University of Sao Paulo, University of São Paulo, São Paulo, Brazil.
Ives Charlie-SilvaDepartment of Pharmacology, University of São Paulo-ICB/USP, São Paulo, Brazil. charliesilva4@hotmail.com.
Jorge Galindo-VillegasDepartment of Genomics, Faculty of Biosciences and Aquaculture, Nord University, Bodø, Norway. jorge.galindo-villegas@nord.no.
Tárcio Teodoro BragaDepartment of Pathology, Federal University of Parana, Curitiba, Brazil. tarcio.braga@ufpr.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite all efforts to combat the pandemic of COVID-19, we are still living with high numbers of infected persons, an overburdened health care system, and the lack of an effective and definitive treatment. Understanding the pathophysiology of the disease is crucial for the development of new technologies and therapies for the best clinical management of patients. Since the manipulation of the whole virus requires a structure with an adequate level of biosafety, the development of alternative technologies, such as the synthesis of peptides from viral proteins, is a possible solution to circumvent this problem. In addition, the use and validation of animal models is of extreme importance to screen new drugs and to compress the organism's response to the disease. Peptides derived from recombinant S protein from SARS-CoV-2 were synthesized and validated by in silico, in vitro and in vivo methodologies. Macrophages and neutrophils were challenged with the peptides and the production of inflammatory mediators and activation profile were evaluated. These peptides were also inoculated into the swim bladder of transgenic zebrafish larvae at 6 days post fertilization (dpf) to mimic the inflammatory process triggered by the virus, which was evaluated by confocal microscopy. In addition, toxicity and oxidative stress assays were also developed. In silico and molecular dynamics assays revealed that the peptides bind to the ACE2 receptor stably and interact with receptors and adhesion molecules, such as MHC and TCR, from humans and zebrafish. Macrophages stimulated with one of the peptides showed increased production of NO, TNF-α and CXCL2. Inoculation of the peptides in zebrafish larvae triggered an inflammatory process marked by macrophage recruitment and increased mortality, as well as histopathological changes, similarly to what is observed in individuals with COVID-19. The use of peptides is a valuable alternative for the study of host immune response in the context of COVID-19. The use of zebrafish as an animal model also proved to be appropriate and effective in evaluating the inflammatory process, comparable to humans.

Indexed as

COVID-19SARS-CoV-2AnimalsHumansMacrophagesPeptidesZebrafishPeptides

Identifiers

PMID37198208
PMCPMC10191404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.